Printer Friendly

COMPANY INFORMATION
Oncothyreon Inc. 2601 Fourth Ave, Suite 500 Seattle, WA, United States 98121 Tel: (206) 801-2100 Fax: (206) 801-2101 Contact Name Investor Relations Industry Biotechnology		Key Executives Robert L. Kirkman, CEO Shashi K. Karan, contr. Researches and develops synthetic vaccines and targeted small molecules for the treatment of cancer.
FP ADVISOR COVERAGE Oncothyreon Inc. • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 364,726 Angiotech Pharmaceuticals, Inc. 319,113 AEterna Zentaris Inc. 72,153 QLT Inc. 48,042 GLG Life Tech Corporation 41,884 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF OCT. 22/09 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta NASDAQ/ONTY $4.53 $8.28 on Aug. 4/09 $4.30 on Oct. 22/09 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap (000s) n.a. n.a. US$ -0.66 Mar. 31/10 n.a. n.a. n.a. $116,663
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/09 12m Dec. 31/08 12m Dec. 31/07 US$000s US$000s US$000s Operating revenue 2,078 39,998 3,798 Net income (17,219) 7,125 (20,340) Total assets 38,225 24,971 36,218 US$ US$ US$ Earnings per share* (0.76) 0.37 (1.04) % % % Return on equity (74.65) 43.53 (59.58)   * Common A Reported in accordance with U.S. GAAP
TRAILING 12-MONTH VALUES Periods ended: June 30/09 June 30/08 US$000s US$000s Operating revenue 36,861 6,286 Net income 8,351 (21,690) US$ US$ Earnings per share 0.45 (1.15)   A Reported in accordance with U.S. GAAP

COMPANY NEWS

Results for 'Oncothyreon Inc.' from past 30 days: No hits. (Links are to articles.)